Your browser doesn't support javascript.
loading
The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers.
van der Lee, Miranda M C; Groothuis, Patrick G; Ubink, Ruud; van der Vleuten, Monique A J; van Achterberg, Tanja A; Loosveld, Eline M; Damming, Désirée; Jacobs, Daniëlle C H; Rouwette, Myrthe; Egging, David F; van den Dobbelsteen, Diels; Beusker, Patrick H; Goedings, Peter; Verheijden, Gijs F M; Lemmens, Jacques M; Timmers, Marco; Dokter, Wim H A.
Afiliação
  • van der Lee MM; Department of Preclinical, Synthon Biopharmaceuticals, Nijmegen, the Netherlands.
  • Groothuis PG; Department of Preclinical, Synthon Biopharmaceuticals, Nijmegen, the Netherlands.
  • Ubink R; Department of Preclinical, Synthon Biopharmaceuticals, Nijmegen, the Netherlands.
  • van der Vleuten MA; Department of Preclinical, Synthon Biopharmaceuticals, Nijmegen, the Netherlands.
  • van Achterberg TA; Department of Preclinical, Synthon Biopharmaceuticals, Nijmegen, the Netherlands.
  • Loosveld EM; Department of Preclinical, Synthon Biopharmaceuticals, Nijmegen, the Netherlands.
  • Damming D; Department of Preclinical, Synthon Biopharmaceuticals, Nijmegen, the Netherlands.
  • Jacobs DC; Department of Preclinical, Synthon Biopharmaceuticals, Nijmegen, the Netherlands.
  • Rouwette M; Department of Preclinical, Synthon Biopharmaceuticals, Nijmegen, the Netherlands.
  • Egging DF; Department of Preclinical, Synthon Biopharmaceuticals, Nijmegen, the Netherlands.
  • van den Dobbelsteen D; Department of Preclinical, Synthon Biopharmaceuticals, Nijmegen, the Netherlands.
  • Beusker PH; Department of Medicinal and Protein Chemistry, Synthon Biopharmaceuticals, Nijmegen, the Netherlands.
  • Goedings P; Department of Medical R&D, Synthon Biopharmaceuticals, Nijmegen, the Netherlands.
  • Verheijden GF; Department of New Molecular Entities, Synthon Biopharmaceuticals, Nijmegen, the Netherlands.
  • Lemmens JM; Department of New Molecular Entities, Synthon Biopharmaceuticals, Nijmegen, the Netherlands.
  • Timmers M; Department of New Molecular Entities, Synthon Biopharmaceuticals, Nijmegen, the Netherlands.
  • Dokter WH; Department of Preclinical, Synthon Biopharmaceuticals, Nijmegen, the Netherlands. Wim.Dokter@Synthon.Com.
Mol Cancer Ther ; 14(3): 692-703, 2015 Mar.
Article em En | MEDLINE | ID: mdl-25589493
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor ErbB-2 / Indóis / Anticorpos Monoclonais Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Holanda
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor ErbB-2 / Indóis / Anticorpos Monoclonais Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Holanda